• About Us
  • Team
  • News
  • Contact
  • About Us
  • Team
  • News
  • Contact

CFN

Home » Home » CFN

Recent Posts
  • Cardurion Pharmaceuticals Announces Appointment of Howard K. Surks, M.D., as Chief Scientific Officer and Head, Translational Medicine
  • Cardurion Pharmaceuticals Announces Appointment of Chris Morabito, M.D., as Chief Medical Officer
  • Cardurion Pharmaceuticals Announces Appointment of Peter Lawrence as President and Chief Executive Officer
  • Cardurion Pharmaceuticals Announces Investment from Polaris Partners and Appoints Amy Schulman to Board of Directors
  • Cardurion Pharmaceuticals Presents Preclinical Data for CRD-733 at the American Heart Association Scientific Sessions and Announces Initiation of Phase 1b Study in Patients with Heart Failure
    CRD-733 treatment reduced or reversed several markers of heart failure and reversed pressure overload-induced cardiac hypertrophy in animal models
Recent Comments
    Archives
    • January 2021
    • July 2020
    • April 2020
    • November 2019
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • April 2018
    • August 2017
    Categories
    • News
    Meta
    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Navigation
    • About Us
    • Team
    • News
    • Contact
    Contact Us

    Cardurion Pharmaceuticals
    Email: info@cardurion.com

    Proudly Built By

    Bellwether Digital